MedTrace Logo

A Phase 1 Study to Evaluate the Safety, Tolerability, PK and PD of SLN124 in Healthy Volunteers

NCT04559971 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2023-04-21

No results posted yet for this study

Summary

This study will evaluate the safety and tolerability of SLN124 in healthy volunteers.

Conditions

  • Healthy Volunteers

Interventions

DRUG

SLN124

SLN124 for subcutaneous (s.c.) injection

DRUG

Placebo

Sodium chloride for s.c. injection

Sponsors & Collaborators

  • Silence Therapeutics plc

    lead INDUSTRY

Principal Investigators

  • Giles Campion, MD · Silence Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-09-03
Primary Completion
2021-03-23
Completion
2021-03-23

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04559971 on ClinicalTrials.gov